Publication,

Cosmetics China: New Ingredients - how to protect the innovator

Current site :    CN   |   EN
Australia
Belgium
China
China Hong Kong SAR
Germany
Italy
Japan
Singapore
Spain
UAE
United Kingdom
United States
Global

How can the brand centric beauty industry which traces its origins to ancient Egypt remain fresh to modern day consumers?

By updating claims and science. Advances in science filter through to greater claims or at least provide consumers with hope that claims can be met. In Europe alone there are 77 scientific innovation facilities that conduct cosmetics research. Nanotechnology is not just for space travel, advanced manufacturing, surgery but also for … skin care. L'Oreal has trademarked "NanoParticles" and has dozens of nanotech patents.
 
New ingredients which are the basis for making new claims are based in science – either as a pure innovation or a new way of dealing with a naturally occurring ingredient. There are new ingredients such as PHAs (polyhydroxy acids) which exfoliate skin; Cica which calms skin irritations; probiotics balance that balance skin conditions; squalane which keeps skin hydrated; tranexamic acid which improve pigmentation … the list goes on. 

Cosmetics have thousands of different ingredients. China's NMPA has approximately 9,000 chemical ingredients that are approved for use in the manufacture of cosmetics for sale in China. If an ingredient is not included in this Inventory of Existing Cosmetic Ingredients in China ("IECIC") then it is considered a "new ingredient" and subject to a registration process. 

This brief will outline ways to protect new ingredient innovations and outline the procedures behind the registration process.



LATEST THINKING
Insight
New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting.

19 May 2022

Publication
Since 2017, KWM has issued the Series, Think Tank Report: Law and Practice under the Belt and Road Initiative. As the fifth instalment of the Series, this pamphlet comprises two parts: “Overview” and “Introduction by Countries”. Authored by KWM lawyers focusing on investment, financing, construction and projects, M&A, trade, compliance, and dispute resolution, this pamphlet will present you our experience and insights from different perspectives.

14 May 2022

Insight
Under the Chinese medical device regulatory regime, as filing/registration is compulsory prior to marketization, the legality of use of unregistered in vitro diagnostics reagents (“IVD”) in laboratory-developed testing (“LDT”) has been in a grey area for a long time.

10 May 2022